FRIDAY, Oct. 27 (HealthDay News) -- Drug-eluting stents result in lower rates of revascularization, and both sirolimus-eluting stents and paclitaxel-eluting stents are safe and effective, according to a report published online Oct. 23 in Circulation: Journal of the American Heart Association.
David O. Williams, M.D., of Rhode Island Hospital in Providence, R.I., and colleagues analyzed data on 6,906 patients from 140 medical centers who underwent percutaneous coronary intervention, of which 397 received bare-metal stents, 3,873 received sirolimus-eluting stents and 2,636 received paclitaxel-eluting stents.
There were significant differences between patients receiving bare-metal stents and drug-eluting stents in terms of clinical characteristics and type of lesion, but no significant difference between those receiving sirolimus-eluting and paclitaxel-eluting stents. Among the bare-metal stent group, the rate of death/myocardial infarction was 9.0 percent versus 5.2 percent for the drug-eluting stent group.
While 9.5 percent of bare-metal stent patients underwent target vessel revascularization, only 6.0 percent of the drug-eluting stent patients did so, while the rates for sirolimus-eluting and paclitaxel-eluting patients were similar at 6.3 percent and 5.5 percent, respectively. However, rates of stent thrombosis were similar for all three groups -- 0.8 percent for bare-metal, 0.5 percent for sirolimus-eluting and 0.8 percent for paclitaxel-eluting stents.
"These observations confirm the effectiveness and safety of both sirolimus-eluting stents and paclitaxel-eluting stents in unselected patients," the authors conclude.
Abstract
Full Text
